KNSA Earnings
Latest Revenue243.6M
Latest Net Income25.4M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.33 | 243.6M | 25.4M | +55.4% | +37.5% |
| Q1 2026 | $0.30 | 214.3M | 22.6M | +55.5% | +150.0% |
| Q4 2025 | $0.19 | 202.1M | 14.2M | +65.0% | +258.3% |
| Q3 2025 | $0.25 | 180.9M | 18.4M | +61.2% | +238.9% |
| Q2 2025 | $0.24 | 156.8M | 17.8M | +44.3% | +500.0% |
| Q1 2025 | $0.12 | 137.8M | 8.5M | +72.5% | +148.0% |
| Q4 2024 | -$0.12 | 122.5M | -8888000 | +46.9% | -133.3% |
| Q3 2024 | -$0.18 | 112.2M | -12693000 | +67.4% | +10.0% |
| Q2 2024 | -$0.06 | 108.6M | -3908000 | — | — |
| Q1 2024 | -$0.25 | 79.9M | -17704000 | — | — |
| Q4 2023 | $0.36 | 83.4M | 25.2M | — | — |
| Q3 2023 | -$0.20 | 67.0M | -13855000 | — | — |
Kiniksa Pharmaceuticals International (KNSA) — Earnings